Goldman Sachs
ORIC icon

Goldman Sachs’s Oric Pharmaceuticals ORIC Stock Holding History

Goldman Sachs’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6M Buy
2,451,796
+976,084
+66% +$8.85M ﹤0.01% 2379
2026
Q1 		$18.7M Sell
1,475,712
-463,573
-24% -$5.26M ﹤0.01% 2490
2025
Q4 		$15.9M Buy
1,939,285
+1,034,473
+114% +$11.9M ﹤0.01% 2605
2025
Q3 		$10.9M Buy
904,812
+415,175
+85% +$4.37M ﹤0.01% 2878
2025
Q2 		$4.97M Buy
489,637
+194,853
+66% +$1.31M ﹤0.01% 3424
2025
Q1 		$1.64M Buy
294,784
+24,778
+9% +$217K ﹤0.01% 4318
2024
Q4 		$2.18M Sell
270,006
-52,619
-16% -$483K ﹤0.01% 4199
2024
Q3 		$3.31M Buy
322,625
+43,815
+16% +$433K ﹤0.01% 3716
2024
Q2 		$1.97M Buy
278,810
+109,132
+64% +$977K ﹤0.01% 3938
2024
Q1 		$2.33M Buy
169,678
+118,890
+234% +$1.41M ﹤0.01% 3764
2023
Q4 		$467K Buy
50,788
+2,632
+5% +$19K ﹤0.01% 4793
2023
Q3 		$291K Sell
48,156
-8,014
-14% -$65.7K ﹤0.01% 4901
2023
Q2 		$436K Sell
56,170
-38,149
-40% -$217K ﹤0.01% 4812
2023
Q1 		$538K Buy
+94,319
New +$493K ﹤0.01% 4778
2022
Q4 		– Sell
-27,557
Closed -$88K – 6193
2022
Q3 		$88K Sell
27,557
-34,830
-56% -$139K ﹤0.01% 5718
2022
Q2 		$280K Buy
62,387
+2,081
+3% +$8.3K ﹤0.01% 5462
2022
Q1 		$322K Buy
60,306
+16,391
+37% +$148K ﹤0.01% 5620
2021
Q4 		$645K Buy
43,915
+3,494
+9% +$54.5K ﹤0.01% 5191
2021
Q3 		$845K Buy
40,421
+6,718
+20% +$136K ﹤0.01% 4884
2021
Q2 		$596K Buy
33,703
+7,383
+28% +$162K ﹤0.01% 5112
2021
Q1 		$645K Buy
26,320
+8,498
+48% +$269K ﹤0.01% 4930
2020
Q4 		$603K Buy
17,822
+4,278
+32% +$123K ﹤0.01% 4501
2020
Q3 		$339K Buy
13,544
+3,280
+32% +$78.1K ﹤0.01% 4670
2020
Q2 		$346K Buy
+10,264
New +$328K ﹤0.01% 4559

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's ORIC Position: Q2 2026 in Review

Goldman Sachs increased its Oric Pharmaceuticals (ORIC) stake by 66% in Q2 2026, buying an estimated $8.85M and bringing the position to 2,451,796 shares worth $26.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

Goldman Sachs first reported a position in ORIC in Q2 2020 and has held it in 24 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Goldman Sachs held 2,451,796 shares of Oric Pharmaceuticals worth $26.6M as of Q2 2026.
  • Goldman Sachs bought 976,084 Oric Pharmaceuticals shares in Q2 2026, an estimated $8.85M.
  • Oric Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2379 holding.
  • Goldman Sachs first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.